@article{ccf23cedbfc74cdeba41a97a8b9427f5,
title = "The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge",
author = "\{Lancet Breast Cancer Commission\} and Coles, \{Charlotte Elizabeth\} and Anderson, \{Benjamin O.\} and David Cameron and Fatima Cardoso and Richard Horton and Knaul, \{Felicia Marie\} and Miriam Mutebi and Naomi Lee and Abraham, \{Jean E.\} and Fabrice Andr{\'e} and Barrios, \{Carlos H.\} and Bliss, \{Judith M.\} and Boughey, \{Judy C.\} and Cameron, \{David A.\} and Cardoso, \{Fatima V.\} and Carey, \{Lisa A.\} and Sanjoy Chatterjee and Jack Cuzick and \{Du Plooy\}, Dorothy and Francis, \{Prudence A.\} and Gralow, \{Julie R.\} and Reshma Jagsi and Fei Ma and Mann, \{Ritse M.\} and McIntosh, \{Stuart A.\} and Mertz, \{Shirley A.\} and Funmi Olopade and Phillips, \{Kelly Anne\} and Poortmans, \{Philip M.\} and Tanja Spanic and Dingle Spence and Hilary Stobart and Symmans, \{Fraser WF\} and Cynthia Villarreal-Garza and Yip, \{Cheng Har\} and Bienz, \{Maya J.\} and Drewett, \{Lynsey M.\} and Alex Fulton and \{Inbah Rajah\}, Dharrnesha and Farasat Kazmi and Jeffrey Rubasingham and Mareike Thompson and Valentina Vargas and Hector Arreola and Badwe, \{Raj A.\} and \{Calderon Anyosa\}, \{Renzo JC\} and Dave, \{Rajiv V.\} and \{De-Graft Aikins\}, Ama and Earl, \{Helena M.\} and Essue, \{Beverley M.\}",
note = "Funding Information: CEC is funded by the National Institute of Health Research (NIHR) and supported by the NIHR Cambridge Biomedical Research Centre. DC reports non-financial interactions unrelated to this Comment with Exact Sciences, Novartis, Lilly, Syntheon, GRAIL, AstraZeneca, Sanofi, Roche, Pfizer, Daiichi-Sankyo, SeaGen, Bexon Consulting, Sapience Therapeutics, and Cytel; research funding unrelated to this Comment, paid to his institution or other institutions, from Amgen, AstraZeneca, Novartis, PFS Exact Sciences, Pfizer, and Roche; and personal fees from AIRC, INCA, SABCS, and Terry Fox Research Institute unrelated to the topic of this Comment. FC reports personal fees from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Debiopharm, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck Sharpe \& Dohme, Merus, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, priME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, and Touchime unrelated to the topic of this Comment. FMK is the founding president of T{\'o}matelo a Pecho, a Mexican non-governmental organisation (NGO), and works in a volunteer capacity; T{\'o}matelo a Pecho receives funding from Merck Sharpe \& Dohme and Higia. FMK is the senior economist of the Mexican Health Foundation, a Mexican NGO, which receives funding from Fundaci{\'o}n Gonzalo R{\'i}o Arronte, and reports consulting fees from Merck KGaA/EMD Serono unrelated to the topic of this Comment. BOA, RH, MM, and NL declare no competing interests. Financial support for Commission meetings and reimbursement for patient advocates has been provided by Breast Cancer Now. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or WHO. ",
year = "2022",
month = mar,
day = "19",
doi = "10.1016/S0140-6736(22)00184-2",
language = "English (US)",
volume = "399",
pages = "1101--1103",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier BV",
number = "10330",
}
